Tenax Therapeutics Inc. (TENX) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Tenax Therapeutics Inc. (NASDAQ: TENX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.80 (+0.56% 1D, market cap $67.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TENX ranks #889 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TENX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TELO (Telomir Pharmaceuticals Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M) and SDEV (Stablecoin Development Corporation) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $67.3M). Among the 5-stock peer group, TENX leads on earnings multiple (N/A) while TENX leads on capital efficiency (-35.0% ROIC).
Per TENX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000034956), Tenax Therapeutics Inc. generated $157.9M in revenue (+189.2% YoY), -$52.6M in net income, and -$35.8M in free cash flow against $104.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 45.2 (NEUTRAL RANGE)
Altman Z-Score 0.23 (DISTRESS RISK (<1.8)) • Piotroski F-Score 2/9
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While TENX currently carries a cautious 27/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.84) and Max Pain ($1.89) forces dealer call-delta covering toward $20.37.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Tenax Therapeutics Inc. (TENX) advanced +0.56% to $1.80, trading at 3% of its 52-week range ($1.31 – $19.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
mykxlg.com report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
Santa Maria Times report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +189.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TENX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TENX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Tenax Therapeutics Inc. (TENX) ranks #889 by composite RQD confidence (27/100, grade E) and #702 by equity capitalization ($67.4M). Within this direct 5-issuer industry benchmark cohort, TENX leads on earnings valuation at N/A trailing P/E, while TENX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SDEV currently holds the highest overall quantitative score in the immediate peer group at 33/100 (E) compared with TENX at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TENX
ACTIVE
Tenax Therapeutics Inc. | E | 27/100 | — | — | -35.0% | +0.56% | $67.4M | Benchmark Subject |
| TELO Telomir Pharmaceuticals Inc. | E | 28/100 | — | — | -35.0% | -2.15% | $67.4M | /telo-vs-tenx → |
| SDEV Stablecoin Development Corporation | E | 33/100 | — | — | -35.0% | -8.91% | $67.3M | /sdev-vs-tenx → |
| MAIA MAIA Biotechnology Inc. | E | 32/100 | — | — | -35.0% | 0.00% | $67.9M | /maia-vs-tenx → |
| QUCY Quantum Cyber N.V. | E | 28/100 | — | 72.6% | -35.0% | -9.61% | $66.2M | /qucy-vs-tenx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tenax Therapeutics Inc. (TENX) reported GAAP revenue of $157.9M (+189.2% vs. FY2024 revenue of $54.6M , and +584.8% cumulative change since FY2023) , GAAP net income of -$52.6M, operating cash flow of -$35.8M, and free cash flow of -$35.8M (-141.7% YoY). On the balance sheet, TENX closed FY2025 with $104.2M in total assets against $0 in total debt (Altman Z-Score: 0.23, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $157.9M | -$52.6M | -$35.8M | -$35.8M | $104.2M | — |
| FY2024 (FY) | 2024-12-31 | $54.6M | -$17.6M | -$14.8M | -$14.8M | $96.7M | — |
| FY2023 (FY) | 2023-12-31 | $23.1M | -$7.7M | -$5.9M | -$5.9M | — | — |
As of 2026-11-03, Tenax Therapeutics Inc. (NASDAQ: TENX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.80 (+0.56% 1D, market cap $67.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TENX ranks #889 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TENX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TELO (Telomir Pharmaceuticals Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M) and SDEV (Stablecoin Development Corporation) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $67.3M). Among the 5-stock peer group, TENX leads on earnings multiple (N/A) while TENX leads on capital efficiency (-35.0% ROIC).
Per TENX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000034956), Tenax Therapeutics Inc. generated $157.9M in revenue (+189.2% YoY), -$52.6M in net income, and -$35.8M in free cash flow against $104.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
TENX last traded at $1.80 (+0.56% on volume of 1,162,695 shares), positioning the stock -2.17% below its 50-day simple moving average ($1.84) and -81.87% below its 200-day simple moving average ($9.93). Across its 52-week range of $1.31 to $19.40, TENX sits at the 2.7% percentile with a 14-day RSI of 45.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.57 to $2.03).
Tenax Therapeutics Inc. (TENX) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.80 (+0.56% 1D, market capitalization $67.4M).
Tenax Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.1B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Tenax Therapeutics Inc. (TENX) reported $157.9M in annual revenue (up from $54.6M in FY2024, +189.2% YoY) and -$52.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($23.1M revenue, -$7.7M net income) through FY2025, TENX scaled operating cash flow to -$35.8M and free cash flow to -$35.8M, backed by $104.2M in total assets against $0 in total debt.
There are no upstream or downstream dependencies, no mapped sector correlations, and no proprietary signals recorded. — For a prospective investor, the absence of mapped links means that second-order ripple effects cannot be assessed from this dataset. The main watch items are the litigation inquiry following the reported Phase 3 failure and whether the company's reported cash position of $97.6M is sufficient relative to its -$35.8M FCF burn in FY 2025.
Real-time company headlines, analyst actions, and sector developments for Tenax Therapeutics Inc. (TENX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
mykxlg.com report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
Santa Maria Times report covering Tenax Therapeutics Inc. (TENX) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on TENX here at $1.79: Reported cash of $97.6M at FY 2025 and institutional accumulation via a 669,800-share SPHERA FUNDS purchase provide some balance-sheet and holder support.. Compare TENX's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $1.70 are getting bought.
@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
Sitting on the sidelines or leaning short TENX above $1.79. A reported Phase 3 trial failure with shares down nearly 90%, a -35% ROIC, an Altman Z of 0.23, and a -$35.8M FY 2025 FCF burn point to a vulnerable balance sheet.. Until Fundamental Cash Engine (3/20) and FCF yield (0.0%) inflect higher, upside is capped near $19.40.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: